RxDoctor Payments Data

Purnima Kothari, MD

Adolescent Medicine · Brooklyn, NYNPI 1952498750

Payments from drug & device makers

$860in general payments, 2019–2025

Across 41 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$590
  • Abbott$150
  • Pfizer$64
  • Kyowa Kirin, Inc.$20
  • Sanofi Pasteur Inc.$20
  • Novartis$16

What the payments were for

  • Food & beverage$82596%
  • Education$354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca35$590
Abbott1$150
Pfizer2$64
Kyowa Kirin, Inc.1$20
Sanofi Pasteur Inc.1$20
Novartis1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 75th percentile of 257 adolescent medicine providers in New York.

See all adolescent medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,330
Medicare patients
31
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol20$30,970
JanuviaSitagliptin Phosphate24$30,152
JanumetSitagliptin Phos/Metformin Hcl21$26,720
LinzessLinaclotide26$22,811
OzempicSemaglutide16$19,891
Breo ElliptaFluticasone/Vilanterol29$12,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,232
Diclofenac Potassium11$4,381
Albuterol Sulfate HfaAlbuterol Sulfate105$3,230
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,783
Atorvastatin Calcium99$720
Metoprolol Succinate35$683
Omeprazole79$631
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide39$577
Losartan Potassium49$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$590$30,97020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 257 adolescent medicine providers in New York.

Other adolescent medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →